Becker Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 55 Published: April 29, 2022 Report Code: GMDGDHC22120IDB

Becker muscular dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects.

Key Targets in the Becker Muscular Dystrophy Pipeline Market

The key targets in the Becker Muscular Dystrophy pipeline market are Androgen Receptor, Cardiolipin, Follistatin, Glucagon Like Peptide 1 Receptor, Glucocorticoid Receptor, Growth/Differentiation Factor 8, Histone Deacetylase 1, Histone Deacetylase 2, Myosin ATPase, and Ryanodine Receptor.

Key MoA in the Becker Muscular Dystrophy Pipeline Market

The key MoA in the Becker Muscular Dystrophy pipeline market are Androgen Receptor Agonist, Follistatin Activator, Glucagon Like Peptide 1 Receptor Agonist, Glucocorticoid Receptor Agonist, Growth/Differentiation Factor 8 Inhibitor, Histone Deacetylase 1 Inhibitor, and Histone Deacetylase 2 Inhibitor.

Key RoA in the Becker Muscular Dystrophy Pipeline Market

The key RoA in the Becker Muscular Dystrophy pipeline market are oral, intravenous, subcutaneous, intramuscular, and ophthalmic. Oral has the highest number of pipeline products.

Becker Muscular Dystrophy Pipeline Market, by RoA

Becker Muscular Dystrophy Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Becker Muscular Dystrophy Pipeline Market

The key molecule types in the Becker Muscular Dystrophy pipeline market are small molecule, fusion protein, gene therapy, monoclonal antibody, recombinant protein, and synthetic peptide. Small molecule has the highest number of pipeline products.

Becker Muscular Dystrophy Pipeline Market, by Molecule Types

Becker Muscular Dystrophy Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Becker Muscular Dystrophy Pipeline Market

The key companies in the Becker Muscular Dystrophy pipeline market are Epirium Bio Inc, ARMGO Pharma Inc, Edgewise Therapeutics Inc, Italfarmaco SpA, Milo Biotechnology LLC, PhaseBio Pharmaceuticals Inc, Santhera Pharmaceuticals Holding AG, and Sarcomed AB. Epirium Bio Inc has the highest number of pipeline products.

Becker Muscular Dystrophy Pipeline Market, by Companies

Becker Muscular Dystrophy Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Androgen Receptor, Cardiolipin, Follistatin, Glucagon Like Peptide 1 Receptor, Glucocorticoid Receptor, Growth/Differentiation Factor 8, Histone Deacetylase 1, Histone Deacetylase 2, Myosin ATPase, and Ryanodine Receptor
Key MoA Androgen Receptor Agonist, Follistatin Activator, Glucagon Like Peptide 1 Receptor Agonist, Glucocorticoid Receptor Agonist, Growth/Differentiation Factor 8 Inhibitor, Histone Deacetylase 1 Inhibitor, and Histone Deacetylase 2 Inhibitor
Key RoA Oral, Intravenous, Subcutaneous, Intramuscular, and Ophthalmic
Key molecule types Small Molecule, Fusion Protein, Gene Therapy, Monoclonal Antibody, Recombinant Protein, and Synthetic Peptide
Key companies Epirium Bio Inc, ARMGO Pharma Inc, Edgewise Therapeutics Inc, Italfarmaco SpA, Milo Biotechnology LLC, PhaseBio Pharmaceuticals Inc, Santhera Pharmaceuticals Holding AG, and Sarcomed AB

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • ARMGO Pharma Inc

    Edgewise Therapeutics Inc

    Epirium Bio Inc

    Italfarmaco SpA

    Milo Biotechnology LLC

    PhaseBio Pharmaceuticals Inc

    Santhera Pharmaceuticals Holding AG

    Sarcomed AB

    Scholar Rock Inc

    Stealth BioTherapeutics Corp

    Tivorsan Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Becker Muscular Dystrophy – Overview

Becker Muscular Dystrophy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Becker Muscular Dystrophy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Becker Muscular Dystrophy – Companies Involved in Therapeutics Development

ARMGO Pharma Inc

Edgewise Therapeutics Inc

Epirium Bio Inc

Italfarmaco SpA

Milo Biotechnology LLC

PhaseBio Pharmaceuticals Inc

Santhera Pharmaceuticals Holding AG

Sarcomed AB

Scholar Rock Inc

Stealth BioTherapeutics Corp

Tivorsan Pharmaceuticals Inc

Becker Muscular Dystrophy – Drug Profiles

apitegromab – Drug Profile

Product Description

Mechanism Of Action

History of Events

ARM-210 – Drug Profile

Product Description

Mechanism Of Action

History of Events

dextro epicatechin – Drug Profile

Product Description

Mechanism Of Action

History of Events

EDG-5506 – Drug Profile

Product Description

Mechanism Of Action

History of Events

elamipretide hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

epicatechin – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis – Drug Profile

Product Description

Mechanism Of Action

History of Events

givinostat – Drug Profile

Product Description

Mechanism Of Action

History of Events

nandrolone decanoate – Drug Profile

Product Description

Mechanism Of Action

PB-1023 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TVN-102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

vamorolone – Drug Profile

Product Description

Mechanism Of Action

History of Events

Becker Muscular Dystrophy – Dormant Projects

Becker Muscular Dystrophy – Discontinued Products

Becker Muscular Dystrophy – Product Development Milestones

Featured News & Press Releases

Apr 14, 2022: Edgewise-Funded natural history trial of Becker Muscular Dystrophy (BMD) now enrolling

Mar 08, 2022: Edgewise Therapeutics to present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference

Jan 05, 2022: Edgewise Therapeutics announces positive topline results from the EDG-5506 phase 1b clinical trial in adults with Becker Muscular Dystrophy (BMD)

Dec 15, 2021: Edgewise Therapeutics to report phase 1b topline results of EDG-5506 in individuals with Becker muscular dystrophy (BMD) on January 5, 2022, and initiates ARCH follow-on open label BMD study

Oct 28, 2021: Edgewise Therapeutics announces positive topline results from the EDG-5506 phase 1 multiple ascending dose (MAD) study in healthy volunteers (HVs) and doses first Becker Muscular Dystrophy (BMD) patients

Sep 27, 2021: ReveraGen and Santhera announce FDA orphan grant funding for clinical trial with vamorolone in Becker muscular dystrophy

Aug 16, 2021: Edgewise receives U.S. FDA Fast Track Designation for EDG-5506 for the treatment of individuals with Becker muscular dystrophy (BMD)

Jun 26, 2021: Italfarmaco announces topline data from phase 2 trial with Givinostat in patients with Becker Muscular Dystrophy

May 04, 2021: Edgewise Therapeutics announces publication of data demonstrating the elevation of fast but not slow skeletal muscle fiber injury biomarkers in the circulation of patients with Becker and Duchenne Muscular Dystrophy

Feb 22, 2021: Italfarmaco provides update on ongoing clinical programs with givinostat in oral presentation at XVIII International Conference on Duchenne and Becker Muscular Dystrophy

Nov 11, 2020: Edgewise Therapeutics initiates phase 1 clinical trial of EDG-5506 in Becker muscular dystrophy

Oct 29, 2020: Edgewise Therapeutics appoints John Moore as general counsel

Aug 12, 2020: Epirium Bio announces commencement of phase 1 clinical trial of EPM-01 in Becker muscular dystrophy

Apr 14, 2020: Epirium Bio receives FDA orphan-drug designation for EB 002 ((+)-Epicatechin) for the treatment of duchenne and becker muscular dystrophy

Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Becker Muscular Dystrophy, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Becker Muscular Dystrophy – Pipeline by ARMGO Pharma Inc, 2022

Becker Muscular Dystrophy – Pipeline by Edgewise Therapeutics Inc, 2022

Becker Muscular Dystrophy – Pipeline by Epirium Bio Inc, 2022

Becker Muscular Dystrophy – Pipeline by Italfarmaco SpA, 2022

Becker Muscular Dystrophy – Pipeline by Milo Biotechnology LLC, 2022

Becker Muscular Dystrophy – Pipeline by PhaseBio Pharmaceuticals Inc, 2022

Becker Muscular Dystrophy – Pipeline by Santhera Pharmaceuticals Holding AG, 2022

Becker Muscular Dystrophy – Pipeline by Sarcomed AB, 2022

Becker Muscular Dystrophy – Pipeline by Scholar Rock Inc, 2022

Becker Muscular Dystrophy – Pipeline by Stealth BioTherapeutics Corp, 2022

Becker Muscular Dystrophy – Pipeline by Tivorsan Pharmaceuticals Inc, 2022

Becker Muscular Dystrophy – Dormant Projects, 2022

Becker Muscular Dystrophy – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Becker Muscular Dystrophy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.